CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop
Bleichmar Fonti & Auld LLP announced a class action lawsuit against Capricor Therapeutics regarding alleged securities fraud tied to the clinical data for Deramiocel. The complaint claims Capricor failed to disclose post-hoc changes to statistical analysis plans, which the firm links to a 64.5% stock drop in July 2026.
Key figures
- Drug Name
- Deramiocel
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.